Mar 31, 2020

Rigel Q1 2020 Earnings Report

Rigel reported first quarter results, including net product sales of $12.7 million and collaboration revenues of $43.1 million.

Key Takeaways

Rigel Pharmaceuticals reported a net income of $21.2 million for the first quarter of 2020, with total revenues of $55.8 million, including $12.7 million in net product sales and $43.1 million in contract revenues from collaborations.

Net product sales increased 57% year over year to $12.7 million.

Collaboration revenues reached $43.1 million due to milestone payment from Grifols.

41 patients enrolled in pivotal Phase 3 clinical trial in warm AIHA.

Received $10.0 million in funding from existing credit facility.

Total Revenue
$55.8M
Previous year: $12.6M
+341.7%
EPS
$1.3
Previous year: -$1.1
-218.2%
Gross Profit
$55.6M
Previous year: $12.5M
+344.2%
Cash and Equivalents
$95.9M
Previous year: $74.7M
+28.4%
Free Cash Flow
-$3.7M
Previous year: -$946K
+291.1%
Total Assets
$95.9M
Previous year: $173M
-44.5%

Rigel

Rigel

Rigel Revenue by Segment

Forward Guidance

Rigel is exploring opportunities for earlier stage programs and believe that they can finalize a collaboration by year end.

Revenue & Expenses

Visualization of income flow from segment revenue to net income